Status:
UNKNOWN
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Solid Tumor
Hematological Malignancy
Eligibility:
All Genders
16-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeri...
Eligibility Criteria
Inclusion
- Patients with lymphoma, leukemia or other malignant diseases who were enrolled for CAR T cell therapy.
Exclusion
- Patients with contraindications indicated in metoprolol instruction, including:
- Significant bradycardia (heart rate \< 45/min)
- Cardiogenic shock
- Severe or acute heart failure
- Poor peripheral circulation perfusion
- Grade II or III atrioventricular block
- Sick sinus syndrome
- Severe peripheral vascular disease
Key Trial Info
Start Date :
September 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04082910
Start Date
September 15 2019
End Date
December 30 2023
Last Update
April 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853